Jenscare Scientific Co., Ltd (HKG: 9877), a leading manufacturer of structural heart disease devices headquartered in Ningbo, has announced the six-month follow-up results from the multi-center TRAVEL II study for its transjugular tricuspid valve replacement product, LuX-Valve Plus.
The TRAVEL II study, a prospective, multi-center, single-arm clinical trial, was designed to evaluate the long-term safety and efficacy of the LuX-Valve Plus in patients with severe tricuspid regurgitation. The study enrolled 96 patients across 15 centers in China. The six-month follow-up data revealed a procedural success rate of approximately 97%, with an average device operation time of 35.56 ± 20.82 minutes. All subjects experienced an improvement in the level of tricuspid regurgitation. In terms of quality of life, the six-month data indicated an average improvement of 20 points in patient scores, demonstrating a significant positive impact. The study also reported that the overall safety profile of the treatment is favorable.- Flcube.com
